Top 5 Contagion® News Articles for the Week of September 17, 2017
SEP 23, 2017 | CONTAGION® EDITORIAL STAFF
#5: New Treatment for CABP Continues to Show Positive Outcomes in Clinical Trials
The leading cause of infectious disease death in the United States is community-acquired bacterial pneumonia (CABP), with more than 5 million adults being treated for the disease each year. The infection is the second highest cause of hospital admissions through the emergency room and because the infection can be severe and potentially life-threatening, many patients end up being readmitted for further treatment. The estimated hospitalization costs to treat the infection are $17 billion. Thus, research and development aimed at a treatment for the infection are booming, and one such company has made an important step forward to bringing a treatment to market.
The clinical-stage biopharmaceutical company, Nabriva Therapeutics, just released positive top-line global Phase 3 trial data on their intravenous (IV) and oral forms of a pleuromutilin antibiotic, lefamulin, for the treatment of community-acquired bacterial pneumonia (CABP) today. The drug met all primary US Food and Drug Administration (FDA) and European Medicines Agency (EMA) endpoints. In this exclusive interview, with Contagion®, Thomas File, MD, MSc, Chair of Infectious Disease Division, Summa Health in Akron, Ohio, explains what pleuromutilin antibiotics are and how they work.
#4: US Government Launches Aggressive New Strategy to Accelerate HIV/AIDS Epidemic Control
Today, September 19, 2017, US Secretary of State, Rex Tillerson, revealed the new the US President’s Emergency Plan for AIDS Relief (PEPFAR) Strategy for Accelerating HIV/AIDS Epidemic Control (2017-2020). This new plan comes on the heels of new Population-based HIV Impact Assessments (PHIA) data from the PEPFAR which shows that 5 African countries are on the brink of fully controlling the HIV epidemics in their countries. Malawi, Swaziland, Zambia, and Zimbabwe are the first 4 countries, and now, new data reveals that Lesotho can be added to the list.
In Lesotho, the newest country added to the list, over 67% of all HIV-positive adults ages 15-59 have been able to achieve viral load suppression, according to the latest PHIA results. These data suggest that the country is well on its way to hit the 90-90-90 targets set forth by the Joint United Nations Programme on HIV/AIDS (UNAIDS) by 2020. PHIA data from 7 additional countries are still being collected and is set to be revealed on a rolling basis through 2017 to 2019.
The new test can differentiate between Lyme disease and 7 other tick-borne diseases.
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512